Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, announced two-year results from the BIOADAPTOR Randomized Controlled (1:1) Trial (RCT), comparing the DynamX® Coronary Bioadaptor System to standard of care Resolute OnyxTM Drug-Eluting
